Graeme Dougherty

Title: Graeme Dougherty: Innovator in Vascular Therapy

Introduction

Graeme Dougherty is a notable inventor based in Los Angeles, CA. He has made significant contributions to the field of medical therapies, particularly in the area of vascular damaging treatments. His innovative approach has led to the development of a unique patent that addresses critical health challenges.

Latest Patents

Dougherty holds a patent for "N-acetylcolchinol-O-phosphate combination therapies with vascular damaging activity." This invention relates to a method for producing a vascular damaging effect in warm-blooded animals, including humans. The method involves administering an effective amount of ZD6126 or a pharmaceutically acceptable salt thereof, either before, after, or simultaneously with therapies such as ionizing radiation, platinum anti-tumor agents, or taxanes. This patent highlights the potential for ZD6126 to enhance the efficacy of existing cancer treatments.

Career Highlights

Graeme Dougherty has established himself as a key figure in the pharmaceutical industry. He is currently associated with AstraZeneca, a leading global biopharmaceutical company. His work focuses on developing innovative therapies that can improve patient outcomes in oncology.

Collaborations

Dougherty has collaborated with various professionals in his field, including his coworker, Peter David Davis. These collaborations have fostered an environment of innovation and have contributed to the advancement of therapeutic strategies in medicine.

Conclusion

Graeme Dougherty's contributions to vascular therapy through his patent and work at AstraZeneca exemplify the impact of innovation in healthcare. His dedication to improving treatment options for patients is commendable and highlights the importance of continued research and development in the medical field.